Sculptor Capital LP Cuts Stock Position in Integer Holdings Corporation $ITGR

Key Points

• Sculptor Capital LP has dramatically reduced its holdings in Integer Holdings Corporation by 99.7% in the first quarter, owning only 28,832 shares worth approximately $3.4 million after selling over 11.4 million shares.
• Several hedge funds have recently adjusted their stakes in Integer, with notable increases from firms such as Hsbc Holdings PLC (up 115.8%) and Northern Trust Corp (up 14.2%).
• Integer reported a net profit margin of 4.61% and increased its revenue by 11.4% year-over-year, along with setting its FY 2025 EPS guidance at 6.250-6.510.

Sculptor Capital LP reduced its stake in Integer Holdings Corporation (NYSE:ITGR - Free Report) by 99.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,832 shares of the medical equipment provider's stock after selling 11,471,168 shares during the quarter. Sculptor Capital LP owned about 0.08% of Integer worth $3,402,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Congress Asset Management Co. boosted its position in shares of Integer by 4.9% in the 1st quarter. Congress Asset Management Co. now owns 522,656 shares of the medical equipment provider's stock worth $61,679,000 after purchasing an additional 24,306 shares in the last quarter. Driehaus Capital Management LLC lifted its position in Integer by 5.5% in the 4th quarter. Driehaus Capital Management LLC now owns 451,464 shares of the medical equipment provider's stock valued at $59,828,000 after acquiring an additional 23,706 shares in the last quarter. Northern Trust Corp lifted its position in Integer by 14.2% in the 4th quarter. Northern Trust Corp now owns 422,380 shares of the medical equipment provider's stock valued at $55,974,000 after acquiring an additional 52,556 shares in the last quarter. Cooke & Bieler LP lifted its position in Integer by 6.3% in the 1st quarter. Cooke & Bieler LP now owns 317,393 shares of the medical equipment provider's stock valued at $37,456,000 after acquiring an additional 18,790 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in Integer by 6.9% in the 1st quarter. Raymond James Financial Inc. now owns 307,141 shares of the medical equipment provider's stock valued at $36,245,000 after acquiring an additional 19,839 shares in the last quarter. 99.29% of the stock is owned by institutional investors.

Insider Transactions at Integer

In other Integer news, Director Martin C. Maxwell sold 8,720 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the sale, the director owned 22,170 shares in the company, valued at approximately $2,672,815.20. This represents a 28.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.16% of the company's stock.

Integer Stock Performance

Shares of NYSE:ITGR traded down $1.24 during midday trading on Wednesday, hitting $105.73. The company had a trading volume of 269,061 shares, compared to its average volume of 469,132. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.41 and a quick ratio of 2.18. The company has a market cap of $3.70 billion, a price-to-earnings ratio of 46.58, a PEG ratio of 0.85 and a beta of 1.03. Integer Holdings Corporation has a 12-month low of $104.93 and a 12-month high of $146.36. The company has a fifty day moving average of $112.21 and a two-hundred day moving average of $117.51.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%.The company had revenue of $476.00 million during the quarter, compared to analysts' expectations of $464.37 million. During the same quarter last year, the company earned $1.30 earnings per share. The company's revenue for the quarter was up 11.4% on a year-over-year basis. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. On average, equities research analysts expect that Integer Holdings Corporation will post 6.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ITGR. Wall Street Zen raised Integer from a "hold" rating to a "buy" rating in a research report on Saturday. Truist Financial lowered their price objective on Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research report on Friday, July 25th. Wells Fargo & Company lowered their price objective on Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research report on Friday, July 25th. Citigroup upgraded shares of Integer from a "hold" rating to a "strong-buy" rating and boosted their target price for the company from $133.00 to $140.00 in a research note on Thursday, May 22nd. Finally, Raymond James Financial decreased their target price on shares of Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a research note on Friday, July 25th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $140.25.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.